The time it takes from acquisition of cytometry data to making actionable decisions is a long and manual process. This impacts the efficiency and quality of the data. The CytoML Suite for in the Aigenpulse Platform automates and enables higher quality insights from cytometry data.
Proteomic technologies hold much potential for the identification potential drug targets, and for the development of protein therapeutics. The Aigenpulse Platform Proteomic Suite helps you to unlock the power of your proteomic data by structuring and integrating all incoming data. Further, the proteomics data is linked to entities which are then available across the Platform, enhancing scientific
Ontologies are sets of concepts with attributes and properties, and the relations between concepts. However, in the biomedical and healthcare sphere, ontologies are large, cumbersome and can be very difficult to add custom terms. With Ontologies management in the Aigenpulse Platform, the complexity is minimised. Our structured flexibility approach drove us to design a system that provides structure for concepts and relations that scales to >100,000s of concepts and >1,000,000s of relations but is easy to use and fast. We provide flexibility whilst keeping this performance but with the ability to add customer or priority terms. All of these ontology terms can be used across the Aigenpulse Platform.
Talk to a Scientist
Speak to one of our scientists to discuss how The Aigenpulse Platform will enhance your multi-omics data.
Imagine a busy lab, where typical workflows span several departments, and data is routinely downloaded on to local laptops in the form of large spreadsheets. Each analysis may need to be done manually, taking several days to perform and all subject to human error. Let the Aigenpulse Platform bring all of your experimental information together, and unlock the power of your data.
One of the biggest hurdles in the development of rationally designed novel therapies is avoiding drug toxicity and side-effects. The less likely a cancer drug candidate is to affect normal, healthy tissues, then the wider the therapeutic window, allowing it to be used at more effective concentrations to treat the disease.